Anidulafungin
Other Antimycotics For Systemic Use
Sold as Ecalta · ERAXIS
- Drug class
- Other Antimycotics For Systemic Use
- Availability
- See label
- Routes
- Intravenous
- Markets covered
- 3
- Products on record
- 8
Overview
Anidulafungin is an active pharmaceutical ingredient in the Other Antimycotics For Systemic Use group (J02AX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 6 | May 1, 2026 |
| EU European Union | EMA | 1 | September 9, 2025 |
| CA Canada | Health Canada | 1 | March 22, 2025 |
GBUnited Kingdom· MHRA
6 products
Uses
1).
How to take
EUEuropean Union· EMA
1 product
Uses
1).
How to take
CACanada· Health Canada
1 product
Uses
ERAXIS (anidulafungin) is indicated for: • treatment of invasive candidiasis/candidemia in non-neutropenic adult and pediatric patients one month and older (see 14 CLINICAL TRIALS) ERAXIS has not been studied in endocarditis, osteomyelitis, or meningitis due to Candida.
Infections caused by C. krusei have not been studied. Neutropenic patients have not been studied in sufficient numbers to determine the efficacy of the drug in this group (see 14 CLINICAL TRIALS). 1 Pediatrics Pediatrics (>1 month and older): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of ERAXIS in pediatric patients has been established.
Therefore, Health Canada has authorized an indication for pediatric use (see 14 CLINICAL TRIALS).
Pediatrics (<1 month):
The safety and efficacy of ERAXIS in pediatric patients <1 month of age has not been established; therefore, Health Canada has not authorized an indication for use in pediatrics <1 month old. 3 Pharmacokinetics, Special Populations and Conditions).
Drug interactions
Known interactions involving Anidulafungin. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB000571563 · revised October 24, 2025
- [2]European Medicines Agency · EMEA/H/C/000788 · revised September 9, 2025
- [3]Health Canada (DPD) · 02330695 · revised March 22, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.